NCT00426842View on ClinicalTrials.gov

A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Orthostatic HypotensionSpinal Cord Injury
Interventions
DRUG

Midodrine Hydrochloride

Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.

Trial Locations (1)

10468

VA Medical Center, Bronx, The Bronx

All Listed Sponsors
lead

James J. Peters Veterans Affairs Medical Center

FED

NCT00426842 - A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride | Biotech Hunter | Biotech Hunter